Results Published on Rhenium-186RNL for Recurrent Glioma

“Peer-reviewed publication of our Phase 1 glioma data in a prestigious, high-impact factor journal is substantial validation for this important clinical program,” said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. “Based largely on this data, our ReSPECT-GBM Phase 2 trial is currently enrolling patients at leading medical centers, bringing us closer to delivering a much-needed treatment option for this devastating disease.”

Key highlights from the publication:

• i. Twenty-one patients were treated with doses up to 22.3 mCi of Rhenium (¹⁸⁶Re) Obisbemeda
• ii. No dose-limiting toxicity was observed, and most adverse events were unrelated to the study treatment
• iii. Median overall survival (OS) was 11 months, surpassing the standard of care for recurrent glioblastoma, which is approximately 8 months
• iv. Median OS was strongly correlated with radiation absorbed dose to the tumor and the percentage of tumor treated
• v. Patients receiving >100 Gy (n=12) had a median OS of 17 months, compared to 6 months for those receiving <100 Gy (n=9) (p=0.001)
• vi,Absorbed radiation doses to the tumor were as high as 739.5 Gy and were delivered without significant toxicity, exceeding levels achievable with external beam radiation therapy.
• Citation: Published: 07 March 2025; Convection enhanced delivery of Rhenium (¹⁸⁶Re) Obisbemeda (¹⁸⁶RNL) in recurrent glioma: a multicenter, single arm, phase 1 clinical trial Andrew J. Brenner,Toral Patel, Ande Bao,et al., Nature Communications volume 16, Article number: 2079 (2025)